Doxorubicin Nanoparticles
Doxorubicin Nanoparticles - Related Videos
08:57
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
0 Views •
Cited by 8 •
2017
This protocol describes an efficient and convenient analytical process of sample extraction and simultaneous determination of multiple drugs, doxorubicin (DOX), mitomycin C (MMC) and a cardio-toxic DOX metabolite, doxorubicinol (DOXol), in the biological samples from a preclinical breast tumor model treated with nanoparticle formulations of synergistic drug combination.
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
0 Views •
Cited by 24 •
2016
A protocol for the preparation and characterization of lipophilic doxorubicin pro-drug loaded 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG) micelles is described.
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
0 Views •
Cited by 49 •
2016
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
10:26
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
0 Views •
Cited by 7 •
2017
Live-cell imaging is a powerful tool to visualize dynamic processes. The examination of fixed cells provides only static pictures, which can lead to misinterpretation and confusion about the process. This work presents a method to study uptake, drug release, and intracellular localization of liposomal nanoparticles in living cells.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
FAQs
Particle design determines how doxorubicin behaves before it reaches a cell. Composition, size, surface chemistry, and the drug-loading strategy can alter particle stability, circulation in the body, cellular uptake, and release. Consequently, changing one design feature may shift the balance between how long the system remains available, how efficiently cells receive the drug, and where exposure occurs.
After delivery, the therapeutic mechanism depends on doxorubicin becoming available to cells. The drug can enter cells, intercalate into DNA, meaning it inserts between DNA components, and disrupt topoisomerase II activity. Nanoparticle engineering therefore affects not only transport but also the timing and location at which this intracellular action can occur.
Controlled release links nanoparticle design with both efficacy and toxicity. If release behavior changes, the timing of doxorubicin availability and cellular exposure may also change. Bioengineers examine this relationship alongside circulation and uptake to investigate whether treatment can be concentrated in tumor tissue while reducing exposure to healthy organs.
A study can assess stability, circulation, cellular uptake, and release, then relate those properties to therapeutic efficacy, pharmacokinetics, and drug-related toxicity. Examining these measurements together helps bioengineers determine how particle design influences delivery behavior and treatment performance, rather than judging the system by drug loading alone.
In bioengineering, these systems provide a platform for examining targeted cancer therapy. Their engineered properties allow investigators to connect nanoscale design with delivery to tumor tissue, intracellular drug action, and exposure of healthy organs. This makes them useful for studying how transport and release decisions affect the balance between therapeutic efficacy and drug-related toxicity.
Pharmacokinetic studies, efficacy measurements, and toxicity assessments provide complementary information about delivery performance. Considering these outcomes together can show whether a nanoparticle design improves treatment in a meaningful way, rather than merely changing circulation or release without a corresponding therapeutic benefit. This integrated view supports comparisons among engineered delivery strategies in cancer research.